

# The Executive Office of Health & Human Services

## Pharmacy and Therapeutics Committee Meeting Minutes



Tuesday, December 15<sup>th</sup>, 2020

8:00 AM

Gainwell Technologies

Location: Virtual

**P & T Members Present:** Greg Allen, MD  
Scott Campbell, RPh  
Todd Brothers, PharmD  
Dave Feeney, RPh, Chairperson  
Matt Salisbury, MD  
Tracey Taveira, PharmD  
Rick Wagner, MD  
Bill Quirk, RPh  
Nickolai Morin, PharmD

**Others Present:** Ann Bennett, MHA (Gainwell Technologies)  
Jerry Fingerut, MD (EOHHS)  
Karen Mariano, RPh (Gainwell Technologies)  
Kathryn Novak, RPh (Magellan Medicaid Administration)

**The meeting was called to order by the Chairperson once a quorum was in attendance - 8:05 am.** Chairman Dave Feeney announces two resignations; his own, and that of Scott Campbell. The chair will transition in 2021 to Tracey Taveira. Co-chair will be voted upon at the April 2021 meeting. Words of thanks were extended to both Dave and Scott for their service and commitment to the RI Medicaid FFS P & T advisory committee.

**The September 15<sup>th</sup>, 2020 meeting minutes were reviewed and by vote were accepted as presented.**

**Public testimony included the following speakers and topics.**

Follow up information should be sent to [karen.mariano@gainwelltechnologies.com](mailto:karen.mariano@gainwelltechnologies.com) for distribution to the committee.

P & T Speaker	Affiliation	Topic
Paul Isikwe	Teva	Austedo
Afraim Bostros	BMS	Zeposia
Jeremiah Rainville	NAMI	
Tom Algozine	Novartis	Kesimpra, Xiidra
Kendra Davies	Greenwich Bioscences	Epidiolex
Steven Burch	Sunovion	Latuda, Kynmobi
Gene Muisse	Amgen	Repatha
Thom Board	Neurocrine Biosciences	Ingrezza
Dylan Bassett	Pierre Fabre	Hemangeol
Samantha Shawn March	MM Wellness Center	Vraylar
Greg Johnson	Neurelis	Valtoco
Susan Steinbis	United Therapeutics	Orenitram
Alix Bennett	Biocodex	Stiripentol
Matthew Clark	Zogenix	Fintepla
Tyson Thompson	Pfizer	Apixiban

Magellan Medicaid Administration (MMA) presented the following categories for therapeutic class reviews with discussion from the pharmacy and therapeutics committee.

Therapeutic Categories	Comments & Discussion	Vote: Yes	Vote: No	Abstain	Motion Pass/Fail
Analgesics	LA Narcotics	No recommended changes to the current preferred agents.	all		pass
	SA Narcotics	No recommended changes to the current preferred agents.	all		pass
	NSAIDS	No recommended changes to the current preferred agents.	all		pass
	Opiate Dependence	Recommended change is the addition of generic tabs buprenorphine/naloxone SL as preferred.	all		pass
	Skeletal Muscle Relaxants	There is no new information and no recommended changes to the current preferred agents.	all		pass
Cardiovascular	Angiotensin Modulators & Combinations	No recommended changes to the current preferred agents.	all		pass
	Anticoagulants	Category update: Coumadin discontinued by manufacturer; generic warfarin remains available. ACC updated bleeding issue guidelines; recommend non-preferring Fragmin.	all		pass
	Beta Blockers	No recommended changes to the current preferred agents.	all		pass
	Calcium Channel Blockers	No recommended changes to the current preferred agents.	all		pass
	Lipotropics, other	Two new drugs Nexletol and Nexlizet; updated indication for Vascepa. No recommended changes to the current preferred agents.	all		pass
	Lipotropics, statins	FDA class wide warning. No recommended changes to the current preferred agents.	all		pass
	PAH Agents	Compliance at zero s because there is low volume of prescriptions in the category. Recommended changes are to prefer ambrisentan and Tracleer, and not prefer Letairis.	all		pass
	Platelet Aggregation Inhibitors	Updated indications Brilinta. No recommended changes to the current preferred agents.	all		pass
	Ranexa	Generic product preferred. No recommended changes to the current preferred agents.	all		pass
	CNS Agents	Alzheimer Agents	No recommended changes to the current preferred agents.	all	
Anticonvulsants		Updated indications. Two 2 new products Xcopri and Fintepla. No recommended changes to the current preferred agents.	all		pass
Antidepressants, other		No recommended changes to the current preferred agents.	all		pass
Antidepressants, SSRI		No recommended changes to the current preferred agents.	all		pass
Antiparkinson Agents		Three new products: Nourianz, Ongentys and Kynmobi. No recommended changes to the current preferred agents.	all		pass
Antipsychotics		New formulation of Secuado. Updated APA guideline, FDA safety communication, new product Caplyta. Discussion; speaker on access to least cost effective. No recommended changes to the current preferred agents.	all		pass

Therapeutic	Categories	Comments & Discussion	Vote: Yes	Vote: No	Abstain	Motion Pass/Fail
CNS Agents (continued)	Movement disorder	New category for committee review. Recommendations to prefer Austedo and tetrabenazine. Refer to DUR to review patients who may be maintained on agent beyond utilization	all			pass
	Multiple Sclerosis	Safety updates; AAN updates. New products are Vumerity, Zeposia, Bafiertam and Kesimpta. Recommended change to non-prefer Rebif and Tysabri.	all			pass
	Neuropathic Pain	Updated indications cymbalta and Qutenza; updated FDA safety indication. No recommended changes to the current preferred agents.	all			pass
	Sedative Hypnotics	New product Dayvigo. No recommended changes to the current preferred agents.	all			pass
	Stimulants & Related Agents	New indication for Wakix. RI child psychiatry group feedback to complement FFS PDL which is comparatively robust. No recommended change to the current preferred agents.	all			pass
	Antihypertensive Sympatholytics	No recommended changes to the current preferred agents.	all			pass
Ophthalmic Agents	Allergic Conjunctivitis	No recommended changes to the current preferred agents.	all			pass
	Antibiotics	No new information. Recommended changes prefer moxifloxacin and ofloxacin, and non-prefer Moxeza and Vigamox.	all			pass
	Antibiotic Steroid Combinations	No recommended changes to the current preferred agents.	all			pass
	Anti-inflammatories	No recommended changes to the current preferred agents.	all			pass
	Anti-inflammatory Immunomodulators	No recommended changes to the current preferred agents.	all			pass
	Glaucoma Agents	No recommended changes to the current preferred agents.	all			pass

## 2021 Schedule

April 13th

June 8th

September 21st

December 14th

## Adjournment

The meeting adjourned at 10:10 AM